Informative censoring — a neglected cause of bias in oncology trials

This publication has 9 references indexed in Scilit:

• Abstract P4-14-03: Influence of competing risks of death on the interpretation of adjuvant endocrine therapy trials for breast cancer
  Cancer Research, 2019
• Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
  New England Journal of Medicine, 2018
• Influence of censoring on conclusions of trials for women with metastatic breast cancer
  European Journal of Cancer, 2015
• Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
  Annals of Oncology, 2014
• Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
  New England Journal of Medicine, 2012
• Censoring in survival analysis: Potential for bias
  Perspectives in Clinical Research, 2012
• Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group
  European Journal of Cancer, 2011
• Issues in Using Progression-Free Survival When Evaluating Oncology Products
  Journal of Clinical Oncology, 2009
• Problems in dealing with missing data and informative censoring in clinical trials
  Current Controlled Trials in Cardiovascular Medicine, 2002